Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | A PML risk genetic test to identify at-risk patients on natalizumab

Eli Hatchwell, MA MB BChir (Cantab) DPhil (Oxon) BA (OU), Population Bio, Oxfordshire, UK, highlights the introduction of a diagnostic panel for assessing the risk of progressive multifocal leukoencephalopathy (PML) in patients. Consisting of four genetic variants across different genes, the test helps categorize patients into risk categories, with those testing positive having ten times the risk of developing PML. This complex disorder, associated with JC virus replication, poses a significant risk to certain MS drug users, most notably with natalizumab. However, Dr Hatchwell underscores the challenge as only a fraction of JC virus-positive patients develop PML. The newly developed test, available for free via, aspires to offer a precision-based approach, aiding patients and clinicians in drug selection. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Employee of Population Bio UK, Inc.